share_log

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

D. Boral Capital發佈買入評級,宣佈將Lineage Cell Therapeutics定價爲$3
Benzinga ·  11/18 23:12  · 評級/大行評級

D. Boral Capital analyst Jason Kolbert initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Buy rating and announces Price Target of $3.

D. Boral Capital 分析師Jason Kolbert對lineage cell therapeutics (美交所:LCTX)啓動覆蓋,給予 買入 評級,並宣佈目標價格爲3美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論